Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 3-year average of 25.94%, near the low end of its 3-year range (0.00%–100.00%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
39.56%
median of 749 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Palvella Therapeutics, Inc.
Market Cap
$1.86B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$1.86B
Gross Margin
9.22%
TTM Avg
11.32%
3Y Avg
13.89%
5Y Avg
14.07%
Market Cap
$1.89B
Gross Margin
64.48%
TTM Avg
64.91%
3Y Avg
63.02%
5Y Avg
55.66%
Market Cap
$1.81B
Gross Margin
72.90%
TTM Avg
70.08%
3Y Avg
67.68%
5Y Avg
66.96%
Market Cap
$1.90B
Gross Margin
78.67%
TTM Avg
83.63%
3Y Avg
79.97%
5Y Avg
53.31%
Market Cap
$1.90B
Gross Margin
70.49%
TTM Avg
67.64%
3Y Avg
66.50%
5Y Avg
65.90%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Palvella Therapeutics, Inc. (PVLA) | $1.86B | 0.00% | 0.00% | 0.00% | N/A |
| Astrana Health, Inc. (ASTH)vs › | $1.86B | 9.22% | 11.32% | 13.89% | 14.07% |
| Azenta, Inc. (AZTA)vs › | $1.83B | 44.05% | 44.96% | 41.63% | 40.93% |
| Novavax, Inc. (NVAX)vs › | $1.84B | 93.67% | 81.97% | 61.43% | 74.28% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 64.48% | 64.91% | 63.02% | 55.66% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.81B | 72.90% | 70.08% | 67.68% | 66.96% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.90B | 78.67% | 83.63% | 79.97% | 53.31% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.90B | 70.49% | 67.64% | 66.50% | 65.90% |
| Novocure Ltd (NVCR)vs › | $1.80B | 76.13% | 75.94% | 76.33% | 77.05% |
| Immunome, Inc. (IMNM)vs › | $1.92B | 57.43% | 78.72% | 64.36% | 42.91% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 96.21% |
| 2023-06-30 | 96.38% |
| 2023-03-31 | 70.51% |
